Tanshinone iia loaded chitosan nanoparticles
Tanshinone iia loaded chitosan nanoparticles has been studied in 1 paper since 2022: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 3, 2022: “Tanshinone IIA loaded chitosan nanoparticles decrease toxicity of β-amyloid peptide in a Caenorhabditis elegans model of Alzheimer's disease”.
1 paper studies it3 findingsUpdated
- 1 lab in 1 country
- Funder: National Natural Science Foundation of China
- Model organisms1
What did studies of Tanshinone iia loaded chitosan nanoparticles find?
3Studies of Tanshinone iia loaded chitosan nanoparticles measured 3 outcomes; the most studied are amyloid-beta deposition (1 study), paralysis (1) and lifespan (1).
Amyloid-beta deposition
downin worms1
1 study
Amyloid-beta deposition
downin worms1
Tanshinone iia loaded chitosan nanoparticles decrease amyloid-beta deposition in worms.
“reducing paralysis and the Aβ deposition by inhibiting the oxidative stress”
Model organismsin CL2006 Alzheimer's disease transgenic model
Free radical biology & medicine
Paralysis
downin worms1
1 study
Paralysis
downin worms1
Tanshinone iia loaded chitosan nanoparticles decrease paralysis in worms.
“attenuate the AD-like symptoms, including reducing paralysis”
Model organismsin CL2006 Alzheimer's disease transgenic model
Free radical biology & medicine
Lifespan
upin worms1
1 study
Lifespan
upin worms1
Tanshinone iia loaded chitosan nanoparticles extend lifespan in worms.
“CS@Tan IIA could significantly prolong the lifespan”
Model organismsin CL2006 Alzheimer's disease transgenic model
Free radical biology & medicine